NCT06167655进行中（未招募）不适用
A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM IN RELIEVING, INTERRUPTING, AND PREVENTING CHRONIC MIGRAINE (RELIEV-CM2)
ShiraTronics45 个研究点 分布在 2 个国家目标入组 250 人开始时间: 2024年5月29日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 250
- 试验地点
- 45
- 主要终点
- Headache Days
研究概览
简要总结
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 22 years of age.
- •Have migraine onset at ≤ 50 years of age.
- •Have a history of migraine for ≥ 12 months prior to screening.
- •Have 15 - 26 headache days/month, among which ≥ 8 days has the features of probable migraine, and minimum of 2 headache-free days/month during the 28-day screening period.
- •Fulfill the criteria for chronic migraine (CM) during the 28-day screening period.
- •Have a diagnosis of refractory chronic migraine (RCM), who have inadequate response or no access to, or are intolerant, unwilling, or contraindicated to Onabotulinum toxin A (Botox) therapy, and One of the medications that belong to Calcitonin Gene Related Peptide Monoclonal antibodies (CGRP) therapy or CGRP antagonist therapy.
- •Maintain a stable use of preventive(s) migraine medication for ≥ 3 months before screening. Subjects receiving OnabotunlinumtoxinA must stop therapy ≥ 3 months prior to screening visit.
- •Demonstrate ≥ 80% compliance with the headache diary during the screening period by entering headache data on a minimum of 22 out of 28 days.
- •Be willing and able to comply with all study procedures and return to the clinic for the follow-up evaluation, as specified in this protocol.
- •Be able to give voluntary, written informed consent to participate in this study.
排除标准
- •Type of headache or migraine other than RCM including the following:
- •Post-traumatic headache (e.g., battlefield, accidents, etc.).
- •Regular intake of opioids (including codeine) of ≥ 8 days in the past 3 months and during the 28-day screening/baseline phase and cannot be accounted for by another diagnosis.
- •Regular intake of Barbiturates for ≥ 5 days/month in the past 3 months and during the 28-day screening/baseline phase and cannot be accounted for by another diagnosis.
- •Report experiencing unremitting, continuous headaches with no relief.
- •Have new daily persistent headache (NDPH) defined by iCHD-3 as persistent headache, daily from its onset, which is clearly remembered. The pain lacks characteristic features and may be migraine-like or tension-type like or have elements of both with a CM subtype.
- •History of treatments that could confound the results of the study
- •Previously implanted neurostimulator to stimulate the greater occipital and/or supraorbital nerves to treat headache.
- •Have received onabotulinumtoxinA (Botox) for any other medical or cosmetic reasons requiring injections in the head, face, or neck within 3 months prior to screening.
- •Have had any cervical radiofrequency ablation within 12 months.
- •Subjects with recent brain or facial trauma occurring less than 3 months prior to the Baseline Visit.
- •Subjects that may have received sequential multi-day in-patient parenteral infusion for the treatment of a migraine condition (e.g., status migrainosus) within the previous 2 weeks of the initiation of diary screening phase.
- •Subjects with any metallic implant located in the head including CSF shunt and surgical clip above the shoulder line (excluding dental implants).
- •Subject has other implanted electrical stimulation device(s) including:
- •Cardiac pacemakers or defibrillators
- •Cochlear implant
- •Intrathecal pumps
- •Spinal cord stimulator
- •Other stimulator device
- •Use of nerve blocks, acupuncture, neurostimulation and/or transcranial magnetic stimulation) for migraine within 3 months prior to screening and after receiving implant system.
- •Any pre-existing or requirement of emergent surgery/procedure that may interfere or confound the results of the study.
- •Any known requirement for an MRI scan subsequent to implant of the neurostimulator.
- •Current or history of following comorbidities:
- •Clinically significant psychiatric illnesses, including suicide attempt, or suicidal ideation with a specific plan in the past 2 years.
- •Cancer in the past 5 years, except for appropriately treated nonmelanoma skin carcinoma.
- •Have a current diagnosis or condition that presents excess risk for performing the procedure, as determined clinically by the Investigator.
- •Substance use disorder of at least moderate severe for substances such as; alcohol, recreational marijuana, or illicit drugs during the past 2 years.
- •Unable to participate or successfully complete the study, in the opinion of the investigator.
- •Anatomy not suitable for placement of the study device.
- •Are currently a study center or Sponsor employee who is directly involved in the study or the relative of such an employee.
- •Pregnant or lactating female or planning a pregnancy during participation in the study.
- •Patient with life expectancy of less than 1.5 years.
- •Currently participating in or planning to participate in other investigational drug or device studies that may interfere or confound the results of the study.
研究组 & 干预措施
High Dose
Active Comparator
干预措施: Neurostimulator (Device)
Low Dose
Sham Comparator
干预措施: Neurostimulator (Device)
结局指标
主要结局
Headache Days
时间窗: 12-weeks
Mean monthly headache days
次要结局
未报告次要终点
研究者
研究点 (45)
Loading locations...
相似试验
已完成
3 期
NeuroAiD II™ (MLC901) in Mild Traumatic Brain InjuryTraumatic Brain InjuryNCT04861688Moleac Pte Ltd.182
已完成
2 期
Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic StrokeAcute Ischemic Stroke (AIS)NCT05585606Silver Creek Pharmaceuticals120
已完成
不适用
Percutaneous Electrical Nerve Field Stimulation for Adults With Irritable Bowel SyndromeAbdominal PainAutonomic Nervous System ImbalanceIrritable Bowel SyndromeNCT04428619University of California, Los Angeles15
终止
2 期
Anamorelin Study for Advanced Pancreatic CancerMetastatic Pancreatic CancerNCT04844970Lahey Clinic4
招募中
不适用
Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual DysfunctionNeurogenic Dysfunction of the Urinary BladderSacral NeuromodulationBowel DysfunctionQuality of LifeMultiple SclerosisSexual DysfunctionNCT05380856Odense University Hospital60